Pardis Mokhtary

Pardis Mokhtary

Auto-generated profile, based on publicly available information

Pardis Mokhtary

Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
PMPardis Mokhtary
Pardis Mokhtary
ZPZeinab Zina Pourhashem
Zeinab Zina Pourhashem
AMAkram Abouei Mehrizi
Akram Abouei Mehrizi
Claudia SalaClaudia Sala
Claudia Sala
RRRino Rappuoli
Rino Rappuoli
Monoclonal antibodies (mAbs), the new revolutionary class of medications, are fast becoming tools against various diseases thanks to a unique structure and function that allow them to bind highly specific targets or receptors. These specialized proteins can be produced in large quantities via the hybridoma technique introduced in 1975 or by means of modern technologies. Additional methods have been developed to generate mAbs with new biological properties such as humanized, chimeric, or murine. The inclusion of mAbs in therapeutic regimens is a major medical advance and will hopefully lead to significant improvements in infectious disease management. Since the first therapeutic mAb, muromonab-CD3, was approved by the U.S. Food and Drug Administration (FDA) in 1986, the list of approved mAbs and their clinical indications and applications have been proliferating. New technologies have been developed to modify the structure of mAbs, thereby increasing efficacy and improving delivery routes. Gene delivery technologies, such as non-viral synthetic plasmid DNA and messenger RNA vectors (DMabs or mRNA-encoded mAbs), built to express tailored mAb genes, might help overcome some of the challenges of mAb therapy, including production restrictions, cold-chain storage, transportation requirements, and expensive manufacturing and distribution processes. This paper reviews some of the recent developments in mAb discovery against viral infections and illustrates how mAbs can help to combat viral diseases and outbreaks.

1 November 2018 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
PMPardis Mokhtary
Pardis Mokhtary
BJBita Javan
Bita Javan
MSMahrokh Sharbatkhari
Mahrokh Sharbatkhari
ASAlireza Soltani
Alireza Soltani
VEVahid Erfani-Moghadam
Vahid Erfani-Moghadam
Introduction: Novel and safe delivery solutions for RNAi therapeutics are essential to obtain the full potential of cancer gene therapy. Methods: In this study, cationic vesicular nanocarrier was applied for delivering lnc urothelial carcinoma-associated 1 (lnc UCA1) shRNA expression vector to MCF-7 cells. The physicochemical characteristics, cytotoxicity, and transfection efficiency of cationic vesicles prepared from various molar ratios of amphiphilic surfactant Tween 80 (T), squalene (S), cationic charge lipid didodecyldimethylammonium bromide, and polyethylenimine were investigated. The particle sizes of the vesicles in the nanosize range were determined by dynamic light scattering and transmission electron microscopy. Results: Gel protection assay with agarose gel electrophoresis showed cationic vesicles can protect the shRNA plasmid from DNase 1 enzyme. 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium, inner salt result showed no significant cytotoxicity was caused in MCF-7 cancer cell line by (T:S):polyethylenimine cationic vesicles. 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium, inner salt assay, fluorescence microscope images, and flow cytometry analyses confirmed that (T:S)1,040 µM with 4.3 µg/mL of PEI vesicles provided effective transfection without significant cytotoxicity. Furthermore, we found efficient UCA1 shRNA transfection and significant (P<0.05) cell cycle arrest and apoptosis in MCF-7 cancer cells. Conclusion: The novel nonviral vesicular nanocarrier, (T:S)1,040 µM with 4.3 µg/mL of PEI, might be safe and efficient for cancer gene therapy and can be used in further in vitro and in vivo studies.

30 April 2021 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
EKelmira karimi
elmira karimi
SBSama Bitarafan
Sama Bitarafan
SMSeyed Mohammad Mousavi
Seyed Mohammad Mousavi
NZNikan Zargarzadeh
Nikan Zargarzadeh
PMPari Mokhtari
Pari Mokhtari
FKFariba koohdani
Fariba koohdani

21 May 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
MTMarco Troisi
Marco Troisi
MFMonica Fabbrini
Monica Fabbrini
SSSamuele Stazzoni
Samuele Stazzoni
VVViola Viviani
Viola Viviani
FCFilippo Carboni
Filippo Carboni
RRRino Rappuoli
Rino Rappuoli
Gonococcus, a bacterium resistant to most antibiotics, causes more than 80 million cases of gonorrhea annually and is considered a high-priority pathogen by the World Health Organization. Recently, vaccine development prospects were boosted by reports that licensed meningococcus serogroup B (MenB) vaccines provided partial protection against gonococcal infection. To determine antigens responsible for cross-protection, memory B cells isolated from 4CMenB-vaccinated volunteers were single cell–sorted to identify antibodies that kill gonococcus in a bactericidal assay. Nine different antibodies, all deriving from the IGHV4-34 germline and carrying an unusually long heavy-chain complementarity-determining region 3, recognized the PorB protein; four others recognized the lipooligosaccharide; and another four had unknown specificity. One of the PorB-specific antibodies provided protection in a mouse model of gonococcus infection. The identification of PorB and lipooligosaccharide as key antigens of gonococcal and meningococcal immunity provides a mechanistic explanation of the cross-protection observed in the clinic and shows that isolating human monoclonal antibodies from vaccinees can be instrumental for bacterial antigen discovery.

8 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MTMarco Troisi
Marco Troisi
MFMonica Fabbrini
Monica Fabbrini
SSSamuele Stazzoni
Samuele Stazzoni
VVViola Viviani
Viola Viviani
FCFilippo Carboni
Filippo Carboni
RRRino Rappuoli
Rino Rappuoli
Gonococcus (Gc), a bacterium resistant to most antibiotics causing more than 80 million cases of gonorrhea annually, is a WHO high priority pathogen. Recently, vaccine development prospects were boosted by reports that licensed meningococcus serogroup B (MenB) vaccines provided partial protection against Gc infection. To determine antigens responsible for cross-protection, memory B cells from 4CMenB vaccinated volunteers were single-cell sorted to identify antibodies that kill Gc in a bactericidal assay. Nine different antibodies, all deriving from the IGHV4-34 germline carrying unusually long HCDR3s, recognized the PorB protein, four recognized the lipooligosaccharide (LOS), and four unknown antigens. One of the PorB antibodies, tested in vivo, provided protection from Gc infection. The identification of PorB and LOS as key antigens of gonococcal and meningococcal immunity provides a mechanistic explanation of the cross-protection observed in the clinic and shows that isolating human monoclonal antibodies from vaccinees can be instrumental for bacterial antigen discovery.

1 December 2021 in Journal of Clinical and Basic Research
Verified
Journal Article
Open access
PDF file
MRMahboobeh Ramezani
Mahboobeh Ramezani
BJBita Javan
Bita Javan
MJMohammad Hasan Jafari
Mohammad Hasan Jafari
ABArsham Banisadr
Arsham Banisadr
MPMahdieh Pourafshar
Mahdieh Pourafshar
MOMorteza Oladnabi
Morteza Oladnabi
Background and objectives: In gene expression studies, to validate and obtain reliable results, normalization of qRT-PCR data by housekeeping genes (HKGs) is required. However, the expression level of these genes may vary in tissues or cells and may change under certain circumstances. Thus, selection of HKGs is critical for gene ...